Zimbabwe has turned down a substantial American healthcare agreement worth $367m (272 million pounds) over five years because of Washington's request for confidential information.
This move became public after a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesman has since explained that the United States was requesting genetic material for scientific study and commercial purposes while was unwilling to share the benefits from future medical innovations.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more dialogue to reach a deal acceptable to all parties so the nation's vital HIV programme can proceed.
Broader Background
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a court suspended a related deal with the US following legal challenges were raised about the security of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump stated its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
As per reports, Sixteen African countries have to date agreed to these new agreements, representing more than $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any equivalent assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," he stated.
"Effectively, our nation would supply the raw materials for scientific discovery without any certainty that the end products would be accessible to our population should a new pandemic arise."
National Interest and International Frameworks
He also noted that the American exit from the global health body and its push of bilateral health agreements were upending systems already established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This mechanism is intended to ensure that when a nation provides its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to develop them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how future co-operation could be designed in a manner that respects the sovereignty and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but recommended that talks must proceed since much of the nation's Aids initiatives relied on external financing.
"Where technical issues exist, such as those involving data governance or agreement terms, these can frequently be addressed via technical clarification and negotiated safeguards," it said.
The situation underscores the complex challenges between receiving vital foreign assistance and protecting national sovereignty in an ever more data-driven world.